You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
福森药业(01652.HK)合营公司江西康德获注资5018万元
格隆汇 12-24 19:26

格隆汇12月24日丨福森药业(01652.HK)宣布,于2019年12月24日,江西康德及江西康德股东与投资者订立注资协议,据此,投资者同意向江西康德注资人民币5018.0415万元,以认购江西康德29.9%的股权,其中人民币426.5335万元将作为江西康德的额外注册资本注入,余下人民币4591.5080万元将计入江西康德的资本储备。由于注资,故投资者以及由公司的全资附属公司衡盛、费久华于光组成的江西康德股东将分别持有江西康德约29.9%、35.8%、21.0%及13.3%的股权,据此,就上市规则而言,江西康德不再为公司的附属公司。于注资后,衡盛于江西康德的股权将由51%摊薄至约35.8%,据此,就上市规则而言,江西康德将不再为公司的附属公司。

然而,鉴于于公告日期,集团于江西康德的股权以权益法于集团的综合财务报表入账为合营企业/联营公司,故根据相关会计准则,尽管注资,江西康德将仍为公司的合营企业/联营公司。因此,预期集团将不会因注资而录得任何重大损益。

于2019年7月12日,公司的全资附属公司衡盛订立收购协议收购菏泽市牡丹区华瀚网络信息技术中心的51%股权,以参与制造及销售名为凯复定的药品(化学名称:注射用头孢他啶),从而扩大集团的医药产品业务及多元化其收入来源。

江西康德为于中国注册成立的有限公司。江西康德主要从事进出口中药材、中药饮片、中成药、化学原料药、药用赋形剂、抗生素原料药物、生化药物及相关技术。江西康德现时进口并向中国市场出售凯复定。

于公告日期,江西康德由公司的全资附属公司衡盛、费久华及于光分别拥有51%、30%及19%的股权。于公告日期,江西康德被视为公司的附属企业,而集团于江西康德的权益乃使用权益法在集团的综合财务报表中入账为合营企业/联营公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account